文献速递新发突发、热带与寄生虫病

桑给巴尔将青蒿琥酯/阿莫地喹作为一线疟疾治疗14年后恶性疟原虫敏感性反而升高

Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar.
PubMed 文献 · Emerg Infect Dis · 2020-01-01

该研究在桑给巴尔通过体内单臂试验和分子标记分析,评估青蒿琥酯/阿莫地喹(ASAQ)作为一线治疗14年后的疗效。结果显示2017年体内疗效(100%;95%CI 97.4%-100%)高于2002-2005年(94.7%;95%CI 91.9%-96.7%)(p=0.003),未发现青蒿素耐药相关基因型,且与阿莫地喹高敏感性相关的基因型较引入ASAQ前大幅增加,提示ASAQ长期使用后疗效维持甚至提高。

要点

  • 桑给巴尔ASAQ使用14年后体内疗效仍为100%,高于早期94.7%。
  • 未检测到青蒿素耐药相关基因型。
  • 与阿莫地喹高敏感性相关的基因型较引入前大幅增加。

核心结论

  • ASAQ在桑给巴尔长期作为一线治疗后疗效维持并似有提高,与非洲其他ACT观察结果不同。

研究设计与样本

  • 在桑给巴尔开展体内单臂试验,并结合恶性疟原虫pfcrt、pfmdr1和Kelch 13 propeller域基因型流行率进行间接分析。

主要发现

  • 2017年体内疗效为100%(95%CI 97.4%-100%),高于2002-2005年的94.7%(95%CI 91.9%-96.7%)(p=0.003)。
  • 分子分析未发现青蒿素耐药相关基因型。
  • 与阿莫地喹高敏感性/疗效相关的基因型较引入ASAQ前大幅增加。

临床怎么用

  • 在桑给巴尔等长期使用ASAQ的地区,该ACT一线治疗仍保持高效,支持继续使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Artemisinin-based combination therapies (ACTs) are first-line treatments for uncomplicated Plasmodium falciparum malaria. ACT resistance is spreading in Asia but not yet in Africa. Reduced effects of ACT partner drugs have been reported but with little information regarding widely used artesunate/amodiaquine (ASAQ). We studied its efficacy in Zanzibar after 14 years as first-line treatment directly by an in vivo, single-armed trial and indirectly by prevalences of different genotypes in the P. falciparum chloroquine-resistance transporter, multidrug-resistance 1, and Kelch 13 propeller domain genes. In vivo efficacy was higher during 2017 (100%; 95% CI 97.4%-100%) than during 2002-2005 (94.7%; 95% CI 91.9%-96.7%) (p = 0.003). Molecular findings showed no artemisinin resistance-associated genotypes and major increases in genotypes associated with high sensitivity/efficacy for amodiaquine than before ASAQ was introduced. Thus, the efficacy of ASAQ is maintained and appears to be increased after long-term use in contrast to what is observed for other ACTs used in Africa.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Msellem M, Morris U, Soe A, et al. Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar. Emerg Infect Dis. 2020. PMID: 32687050. doi:10.3201/eid2608.191547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。